Under the heavy pressure of a 200% pharmaceutical tariff, Biogen (BIIB.US) has added an additional $2 billion investment to expand its US factory.

Biogen (BIIB.US) announced on Monday that it will invest an additional $2 billion in its existing factory in North Carolina. This move is aimed at expanding its business in the United States to counter the tariff threats from U.S. President Donald Trump. Biogen joins the ranks of other major pharmaceutical companies such as Eli Lilly (LLY.US), Roche, and Merck & Co., Inc. (MRK.US), which have all announced investments in the United States in response to potential import tariffs. So far, pharmaceuticals have not been impacted by Trump's policy of implementing reciprocal tariffs, but he has been advocating for separate tariffs to promote American manufacturing and avoid relying on other countries for drug supply. Earlier this month, Trump suggested that drug tariffs might be delayed, but rates could go as high as 200%. Biogen announced on Monday that it will invest in the Research Triangle Park (RTP) in North Carolina. This park is where its largest manufacturing facilities are located, producing key drugs for the treatment of multiple sclerosis and Alzheimer's disease. The investments will enhance the company's capabilities in developing and producing certain gene-targeted therapies, as well as adding filling and packaging facilities, introducing automation technology, and artificial intelligence. The pharmaceutical company has already invested around $10 billion in its production facilities in North Carolina. Biogen has 7 factories in the state, with the 8th factory expected to be operational in the second half of 2025.